New Blood Tests Catch Alzheimer's Earlier Than Ever

For the first time, a simple blood draw can detect Alzheimer's disease in its earliest stages, transforming how doctors diagnose this devastating condition.

The FDA has approved two blood tests that measure tau and amyloid proteins linked to Alzheimer's, with several more tests awaiting approval. These tests work for adults 55 and older who show early memory problems, helping specialists confirm diagnoses without expensive brain scans or painful spinal taps.

Dr. Sebastian Palmqvist, a neurologist at Lund University in Sweden, says the tests detect "a core part of the pathology of Alzheimer's disease in the brain." The proteins they measure form sticky plaques and tangles that damage brain cells as the disease progresses.

Right now, memory clinic specialists use these blood tests alongside other exams to provide accurate diagnoses. While the tests alone can't confirm Alzheimer's, they dramatically simplify the process for patients showing subtle changes in memory or personality.

The timing couldn't be better. New disease-modifying drugs like lecanemab and donanemab became available in recent years, offering the first treatments that actually slow Alzheimer's progression rather than just managing symptoms.

Researchers agree that catching the disease early gives these medications the best chance to help. The goal is removing harmful proteins before they cause significant brain damage.

Why This Inspires

What makes this breakthrough truly hopeful is its accessibility. Before these blood tests, confirming Alzheimer's meant undergoing expensive imaging procedures or invasive lumbar punctures that many patients couldn't access or afford.

Now, a routine blood draw at a memory clinic can provide answers. Data presented at the recent Alzheimer's Association International Conference in London suggests these tests might eventually help primary care doctors make accurate diagnoses too, bringing specialized care to more communities.

Dr. Jemma Hazan, a psychiatrist at University College London, emphasizes using these tests where patients can get proper guidance on next steps. When someone tests positive, they gain earlier access to clinical trials, new treatments, and support systems that work best in early stages.

While Alzheimer's remains incurable, patients diagnosed today face better options than those diagnosed just a decade ago. These blood tests represent another step toward catching the disease when treatments matter most, giving families more time and better outcomes.

The science is clear: simpler testing means earlier diagnosis, and earlier diagnosis means better chances for the treatments of today and tomorrow.